C. diff Risk


Oral Bioavailability


Spectrum Of Activity


500-750 mg PO BID

400 mg IV q8-12h

30+ mL/min10 - 30 mL/min0 - 10 mL/min500-750 mg PO BID500-750 mg PO daily250-500 mg PO daily

30+ mL/min0 - 30 mL/min400 mg IV q8-12h400 mg IV q24h

500-750 mg PO q24h - give after dialysis on dialysis days

400 mg IV q24h - give after dialysis on dialysis days

400 mg IV q12h

500-750 mg PO q24h

400 mg IV q24h

General Information

Additional Information

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.

Adverse Effects

  • QTc prolongation

  •  Dysglycemia

  •  CNS toxicity including confusion, psychosis

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • Rash

  • Retinal detachment

Drug Monitoring

Monitor QTc in patients with increased risk

Major Interactions

  • CYP1A2 inhibitor - multiple interactions possible

  •  QTc prolongation - Increased risk with other agents that prolong QTc

  •  Di- & Trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - decreased absorption

  •  Cyclosporine - increased levels of cyclosporine

  •  Warfarin - increased INR

  •  Decreases phenytoin levels


Antimicrobial class: Fluoroquinolone

Pregnancy category: C